How to buy Regeneron Pharmaceuticals stock (REGN)

Regeneron Pharmaceuticals is a biotech company headquartered in New York. While it works on a number of drugs and diseases, it's most recently been in the news for REGN-COV2 — the experimental antibody cocktail.

The antibody cocktail is being studied as a possible treatment for the novel coronavirus.

Our top picks for where to buy Regeneron Pharmaceuticals stock

Buy Regeneron Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Regeneron Pharmaceuticals stock price (NASDAQ: REGN)

Use our graph to track the performance of REGN stocks over time.

Regeneron Pharmaceuticals shares at a glance

• Live prices
• Key figures

Information last updated 2024-12-17.

Open	$0.00
High	$0.00
Low	$0.00
Close	$0.00
Previous close	$0.00
Change more info button	$0.00
Change % more info button	N/A%
Volume more info button	0

Information last updated 2024-12-12.

52-week range	$735.95 - $1,211.20
50-day moving average more info button	$872.04
200-day moving average more info button	$990.91
Wall St. target price	$1,052.75
PE ratio more info button	19.1195
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$40.43

Is it a good time to buy Regeneron Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Regeneron Pharmaceuticals price performance over time

Historical closes compared with the close of $724.87 from 2024-12-13

1 week (2024-12-10)	-6.89%
1 month (2024-11-15)	-4.22%
3 months (2024-09-17)	-36.79%
6 months (2024-06-17)	-30.66%

1 year (2023-12-15)	-15.63%
2 years (2022-12-16)	0.24%
3 years (2021-12-17)	17.05%
5 years (2019-12-17)	96.39%

Is Regeneron Pharmaceuticals stock undervalued or overvalued?

Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Regeneron Pharmaceuticals's P/E ratio

Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Regeneron Pharmaceuticals shares trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Regeneron Pharmaceuticals's PEG ratio

Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1503. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Regeneron Pharmaceuticals's EBITDA

Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.6 billion.

The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Regeneron Pharmaceuticals financials

Revenue TTM	$13.8 billion
Operating margin TTM	33.43%
Gross profit TTM	$7 billion
Return on assets TTM	7.41%
Return on equity TTM	17.17%
Profit margin	33.61%
Book value	$272.04
Market Capitalization more info button	$84.9 billion

TTM: trailing 12 months

Regeneron Pharmaceuticals share dividends

We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months.

Regeneron Pharmaceuticals share price volatility

Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as $735.95 up to $1211.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.142. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).

Regeneron Pharmaceuticals overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc.

Frequently asked questions

What percentage of Regeneron Pharmaceuticals is owned by insiders or institutions?
Currently 1.563% of Regeneron Pharmaceuticals shares are held by insiders and 90.64% by institutions. How many people work for Regeneron Pharmaceuticals?
Latest data suggests 14,165 work at Regeneron Pharmaceuticals. When does the fiscal year end for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals's fiscal year ends in December. Where is Regeneron Pharmaceuticals based?
Regeneron Pharmaceuticals's address is: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 What is Regeneron Pharmaceuticals's ISIN number?
Regeneron Pharmaceuticals's international securities identification number is: US75886F1075 What is Regeneron Pharmaceuticals's CUSIP number?
Regeneron Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 75886F107